Current Guidelines and Future Directions in Colorectal Cancer Treatment

References


Bendell JC, Atreya CE, André T, et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol. 2014;32:5s(suppl; abstr 3515).


Hegewisch-Becker S, Graeven U, Lerchenmüller C, et al. Maintenance strategy with fluoropyrimidines (FP) plus bevacizumab (Bev), alone or no treatment following a 24-week first-line induction with FP, oxaliplatin (Ox) and Bev for patients with metastatic colorectal cancer: mature data and subgroup analysis of the AIO KRK 0207 phase III study (abstr 4980). Presented at: European Society for Medical Oncology (ESMO); September 26-30, 2014; Madrid, Spain.


Hong Y-S, Byung-Ho Nam B-H, Kim K-P, et al. Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE). J Clin Oncol. 2014;32:5s(suppl; abstr 3502).


Lenz H-J. CALGB/SWOG 80405: Phase III trial of FOLFIRI or mFOLFOX6 with bevacizumab or cetuximab for patients with expanded RAS analyses in untreated metastatic adenocarcinoma of the colon or rectum. Presented at: European Society for Medical Oncology (ESMO); September 26-30, 2014; Madrid, Spain.


National Comprehensive Cancer Care Network (NCCN) Rectal Cancer Guideline, v2.2015.


Tabernero J, Cohn AL, Obermannova R, et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol. 2015;33(suppl 3; abstr 512).


Van Cutsem E, Ohtsu A, Falcone A, et al. Phase III RECURSE trial of TAS-102 vs. placebo with best supportive care (BSC) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (abstr LBA13). Presented at: European Society for Medical Oncology (ESMO); September 26-30, 2014; Madrid, Spain.


Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). *J Clin Oncol.* 2014;32:5s(suppl; abstr LBA3).
